The estimated Net Worth of Randall W Whitcomb is at least $99.8 Tisíc dollars as of 10 March 2015. Randall Whitcomb owns over 1,750 units of Millendo Therapeutics stock worth over $73,339 and over the last 21 years Randall sold MLND stock worth over $26,460.
Sign up
Randall Whitcomb MLND stock SEC Form 4 insiders trading
Randall has made over 5 trades of the Millendo Therapeutics stock since 2003, according to the Form 4 filled with the SEC. Most recently Randall exercised 1,750 units of MLND stock worth $11,375 on 10 March 2015.
The largest trade Randall's ever made was selling 9,000 units of Millendo Therapeutics stock on 5 August 2003 worth over $26,460. On average, Randall trades about 1,023 units every 193 days since 2003. As of 10 March 2015 Randall still owns at least 69,188 units of Millendo Therapeutics stock.
You can see the complete history of Randall Whitcomb stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Randall Whitcomb's mailing address?
Randall's mailing address filed with the SEC is C/O MILLENDO THERAPEUTICS, INC., 301 N. MAIN ST., SUITE 100, ANN ARBOR, MI, 48104.
What does Millendo Therapeutics do?
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
What does Millendo Therapeutics's logo look like?
Complete history of Randall Whitcomb stock trades at Insmed Inc a Millendo Therapeutics
Millendo Therapeutics executives and stock owners
Millendo Therapeutics executives and other stock owners filed with the SEC include:
-
Julia Owens,
President, Chief Executive Officer, Director -
Louis Arcudi,
Chief Financial Officer -
Ryan Zeidan,
Chief Development Officer -
Dr. Julia C. Owens Ph.D.,
Exec. Chair of Board -
Louis J. Arcudi III, M.B.A., MBA,
CEO, Pres & Director -
Carol Gallagher,
Independent Chairman of the Board -
Connie Chang,
Vice President - Corporate Affairs -
Carole Nuechterlein,
Independent Director -
John Howe,
Independent Director -
James Hindman,
Independent Director -
Mary Hedley,
Independent Director -
Habib Dable,
Independent Director -
Geoffrey Nichol,
Independent Director -
Thomas Hoover,
Chief Commercial Officer -
Christophe Arbet-Engels,
Chief Medical Officer -
Tamara Joseph,
General Counsel, Corporate Secretary -
Denise Dorigo Jones,
VP of HR -
Jeffery M. Brinza J.D.,
Interim Gen. Counsel -
Jennifer Lynn Minai-Azary,
CFO & Principal Accounting Officer -
Jeffery M. Brinza,
Sec., CAO and General Counsel -
Randall W Whitcomb,
Director -
Pharis Mohideen,
Chief Medical Officer -
Jennifer Lynn Minai Azary,
Chief Financial Officer